“Global office based lab market will cross 10.0 billion revenues by 2030”, says Visiongain

23 January 2020
Pharma

Visiongain’s new report the Office Based Lab Market Forecast 2020-2030: Forecasts by Modality (Single Specialty, Multi-Specialty) By Service (Peripheral Vascular Intervention, Endovascular Interventions, Cardiac, Interventional radiology, Venous, Others), by Specialty (Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Others) plus analysis of leading companies indicates that the global office based lab market will cross 10.0 billion revenues by 2030.

The growing trend of surgical procedures in ambulatory settings, driven by the rising occurrence of various vascular diseases, is one of the major factors driving U.S. demand for Office-based laboratories (OBL). In addition, high patient satisfaction is expected to boost the market with a focused and dedicated team of doctors.

Several service providers are available in the country, such as National Cardiovascular Partners and Envision Healthcare and Surgery Partners, and have provided patients with an affordable cost of office-based surgical solutions and services. In fact, key companies including Philips Healthcare & Siemens Healthineers have collaborated with physicians to set up OBLs, equip laboratories with the requisite instruments and provide integrated solutions from start to finish, which are expected to drive the market forward.

The global OBL industry is facing challenges such as limited availability of anesthetic tools and services that may jeopardize patient safety, and lack of technical expertise for minimally invasive surgical procedures. The lack of definitive training and education programs for the use of MIS devices makes surgeons unwilling to use this technology in OBL settings.

Single-specialty OBLs provide more patient-centered services with minimal risk of corporate partner divestment. On the other hand, hybrid models offer greater flexibility under one roof with multiple facilities. The high cost of setting up such laboratories, however, may restrict their establishment. Multi-specialty laboratories are also becoming more common as a collaboration between three and five physicians.

The interventional radiologists segment is expected to see lucrative growth during the forecast period with growing acceptance of minimally invasive procedures in office settings. Similar to vascular surgeons, interventional radiologists participate in more complicated procedures such as coil embolization.

The definition of OBLs was embraced and applied most commonly in the U.S. Today, about 70% of surgical procedures are conducted in ambulatory settings, of which about 25% of the procedures are done in the office of a doctor. The idea of OBL was developed specifically to concentrate on vascular surgery in the office setting, providing patients with more effective treatment at a lower cost. Due to the high incidence of atherosclerosis in the country and a large number of balloon angioplasty and stenting procedures in patients with blocked arteries and veins, peripheral vascular interventions (PVI) dominated the market in services.

This market's supplier environment can be classified into three different sectors: manufacturers of medical imaging equipment, manufacturers of vascular intervention equipment and service providers providing physicians end-to-end solutions to set up laboratories.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

Read

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

Read

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever